NASDAQ · NRIX
Nurix Therapeutics, Inc.
$27.12-$0.14 (-0.51%)
Nurix Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.93% below the high.
Loading market information…
NASDAQ · KURA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Kura Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.03% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Kura Oncology, Inc.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of -$0.82. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Kura Oncology, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 1, 2025 | -$0.66-29.41% vs estimate | $14.11M-78.84% vs estimate |
|---|
| Q4 2024 | Feb 26, 2025 | -$0.22+66.15% vs estimate | $53.88M-7.04% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.63+1.56% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
17 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 9 contributors · Median target $24.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$27.12-$0.14 (-0.51%)
Nurix Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.93% below the high.
$13.59+$0.27 (+2.03%)
HUTCHMED (China) Limited’s quoted price sits in the upper half of its reported 52-week range, 16.78% below the high.
$10.16-$0.23 (-2.17%)
SELLAS Life Sciences Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 36.05% below the high.
$21.48-$0.27 (-1.24%)
Tyra Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.16% below the high.
$14.15-$0.17 (-1.19%)
Syndax Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.7% below the high.
$51.45+$0.71 (+1.4%)
Rigel Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.51% below the high.
$8.99-$0.31 (-3.33%)
ORIC Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.76% below the high.
$9.66-$0.18 (-1.78%)
Verastem, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.72% below the high.
